Cargando…

Cardiomyocyte Inflammasome Signaling in Cardiomyopathies and Atrial Fibrillation: Mechanisms and Potential Therapeutic Implications

Inflammasomes are high molecular weight protein complexes in the cytosol of immune and other cells that play a critical role in the innate immune system in response to cellular stress. NLRP3 inflammasome, the best-understood inflammasome, is known to mediate the maturation (activation) of caspase-1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Gong, Chelu, Mihail G., Dobrev, Dobromir, Li, Na
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Physiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6100656/ https://www.ncbi.nlm.nih.gov/pubmed/30150941 http://dx.doi.org/10.3389/fphys.2018.01115

Ejemplares similares

Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology
por: Dobrev, Dobromir, et al.
Publicado: (2022)

COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications
por: Gawałko, Monika, et al.
Publicado: (2020)

Atrial Fibrillation Mechanisms and Implications for Catheter Ablation
por: Cheniti, Ghassen, et al.
Publicado: (2018)

Sleep apnea and atrial fibrillation: Update 2020
por: Linz, Dominik, et al.
Publicado: (2020)

Left Atrial Hypertension, Electrical Conduction Slowing, and Mechanical Dysfunction – The Pathophysiological Triad in Atrial Fibrillation-Associated Atrial Cardiomyopathy
por: Eichenlaub, Martin, et al.
Publicado: (2021)

Linking Electrical Drivers With Atrial Cardiomyopathy for the Targeted Treatment of Atrial Fibrillation
por: Ho, Gordon, et al.
Publicado: (2020)

Profibrotic, Electrical, and Calcium-Handling Remodeling of the Atria in Heart Failure Patients With and Without Atrial Fibrillation
por: Molina, Cristina E., et al.
Publicado: (2018)

Emerging Antiarrhythmic Drugs for Atrial Fibrillation
por: Saljic, Arnela, et al.
Publicado: (2022)

Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update
por: Tsuji, Yukiomi, et al.
Publicado: (2013)

Antiarrhythmic drugs for atrial fibrillation: Imminent impulses are emerging
por: Dan, Gheorghe-Andrei, et al.
Publicado: (2018)

The temporal context of oral anticoagulation outcome in atrial fibrillation
por: Fender, Anke C., et al.
Publicado: (2022)

Premature atrial contractions: A predictor of atrial fibrillation and a relevant marker of atrial cardiomyopathy
por: Guichard, Jean-Baptiste, et al.
Publicado: (2022)

Altered Atrial Metabolism: An Underappreciated Contributor to the Initiation and Progression of Atrial Fibrillation
por: Ghezelbash, Shokoufeh, et al.
Publicado: (2015)

Bayesian network analyses in atrial fibrillation – A path to better therapies?()
por: Heijman, Jordi, et al.
Publicado: (2019)

Pleiotropic Effects of Antiarrhythmic Agents: Dronedarone in the Treatment of Atrial Fibrillation
por: Heijman, Jordi, et al.
Publicado: (2013)

Surgery-related cardiac stress: A susceptibility test of late atrial fibrillation recurrence?
por: Gawałko, Monika, et al.
Publicado: (2020)

Fat chance for POAF? Pericardial adipose tissue and the arrhythmogenic substrate for postoperative atrial fibrillation
por: Gawałko, Monika, et al.
Publicado: (2022)

Botulinum toxin for prevention of post-operative atrial fibrillation
por: Saljic, Arnela, et al.
Publicado: (2023)

Outcome of atrial fibrillation ablation in pulmonary hypertension: Is pulmonary hypertension a modifiable risk factor?
por: Linz, Dominik, et al.
Publicado: (2019)

Calcium dysregulation in atrial fibrillation: the role of CaMKII
por: Heijman, Jordi, et al.
Publicado: (2014)

Genome-wide association studies of atrial fibrillation: Finding meaning in the life of risk loci
por: Sutanto, Henry, et al.
Publicado: (2019)

Cardiomyocyte-Derived Exosomes: Biological Functions and Potential Therapeutic Implications
por: Yu, Hui, et al.
Publicado: (2019)

PITX2 gain-of-function mutation associated with atrial fibrillation alters mitochondrial activity in human iPSC atrial-like cardiomyocytes
por: Benzoni, Patrizia, et al.
Publicado: (2023)

Chronic kidney disease promotes atrial fibrillation via inflammasome pathway activation
por: Song, Jia, et al.
Publicado: (2023)

Atrial fibrillation in sub-Saharan Africa: The knowns and unknowns?
por: Linz, Dominik, et al.
Publicado: (2019)

Genotype-Driven Pathogenesis of Atrial Fibrillation in Hypertrophic Cardiomyopathy: The Case of Different TNNT2 Mutations
por: Pioner, Josè Manuel, et al.
Publicado: (2022)

Anticoagulation in difficult settings RELOADed: Evidence for applicability of direct oral anticoagulants in patients with atrial fibrillation, renal impairment and cancer
por: Fender, Anke C., et al.
Publicado: (2019)

Breaking bad: Higher risk of osteoporosis with vitamin K antagonists compared to direct oral anticoagulants in patients with atrial fibrillation
por: Fender, Anke C., et al.
Publicado: (2020)

Recent highlights from the International Journal of Cardiology Heart & Vasculature on challenges for adequate stroke prevention in patients with atrial fibrillation
por: Fender, Anke C., et al.
Publicado: (2023)

Reactive oxygen species-targeted therapeutic interventions for atrial fibrillation
por: Sovari, Ali A., et al.
Publicado: (2012)

Gut-microbiota derived TMAO: A risk factor, a mediator or a bystander in the pathogenesis of atrial fibrillation?
por: Gawałko, Monika, et al.
Publicado: (2021)

TGF-β1–induced endothelial-mesenchymal transition: a potential contributor to fibrotic remodeling in atrial fibrillation?
por: Saljic, Arnela, et al.
Publicado: (2022)

NLRP3 Inflammasome as a Molecular Marker in Diabetic Cardiomyopathy
por: Luo, Beibei, et al.
Publicado: (2017)

Inhibition of EPAC1 signaling pathway alters atrial electrophysiology and prevents atrial fibrillation
por: Guillot, Bastien, et al.
Publicado: (2023)

Epigenetic Mechanism and Therapeutic Implications of Atrial Fibrillation
por: Li, Dan, et al.
Publicado: (2022)

Toward Mechanism-Directed Electrophenotype-Based Treatments for Atrial Fibrillation
por: Ng, Fu Siong, et al.
Publicado: (2020)

Cardiomyocyte Hypocontractility and Reduced Myofibril Density in End-Stage Pediatric Cardiomyopathy
por: Bollen, Ilse A. E., et al.
Publicado: (2017)

The gut microbial-derived metabolite trimethylamine N-oxide: A missing link between lifestyle-components and atrial fibrillation?
por: Gawałko, Monika, et al.
Publicado: (2020)

Arrhythmia mechanism dependent pulmonary vein ablation in paroxysmal atrial fibrillation
por: Gottlieb, Lisa A., et al.
Publicado: (2023)

Double Jeopardy: Will the new trials tell us how to manage patients with atrial fibrillation and coronary artery disease?
por: Wakili, Reza, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_027nfvatsdao14brn6p6lls2mn